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Abstract
CD4 positive T helper cells control many aspects of specific immunity. These cells are specific for peptides derived from
protein antigens and presented by molecules of the extremely polymorphic major histocompatibility complex (MHC) class II
system. The identification of peptides that bind to MHC class II molecules is therefore of pivotal importance for rational
discovery of immune epitopes. HLA-DR is a prominent example of a human MHC class II. Here, we present a method,
NetMHCIIpan, that allows for pan-specific predictions of peptide binding to any HLA-DR molecule of known sequence. The
method is derived from a large compilation of quantitative HLA-DR binding events covering 14 of the more than 500 known
HLA-DR alleles. Taking both peptide and HLA sequence information into account, the method can generalize and predict
peptide binding also for HLA-DR molecules where experimental data is absent. Validation of the method includes
identification of endogenously derived HLA class II ligands, cross-validation, leave-one-molecule-out, and binding motif
identification for hitherto uncharacterized HLA-DR molecules. The validation shows that the method can successfully predict
binding for HLA-DR molecules—even in the absence of specific data for the particular molecule in question. Moreover,
when compared to TEPITOPE, currently the only other publicly available prediction method aiming at providing broad HLA-
DR allelic coverage, NetMHCIIpan performs equivalently for alleles included in the training of TEPITOPE while outperforming
TEPITOPE on novel alleles. We propose that the method can be used to identify those hitherto uncharacterized alleles,
which should be addressed experimentally in future updates of the method to cover the polymorphism of HLA-DR most
efficiently. We thus conclude that the presented method meets the challenge of keeping up with the MHC polymorphism
discovery rate and that it can be used to sample the MHC ‘‘space,’’ enabling a highly efficient iterative process for improving
MHC class II binding predictions.
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Introduction
Major histocompatibility complex (MHC) molecules play an
essential role in the host-pathogen interactions determining the
onset and outcome of many host immune responses. While
peptides derived from foreign, intracellular proteins and presented
in complex with MHC class I molecules can trigger a response
from cytotoxic T lymphocytes (CTL), MHC class II molecules
present peptides derived from proteins taken up from the extra-
cellular environment. They stimulate cellular and humoral
immunity against pathogenic microorganisms through the actions
of helper T lymphocytes. Only a small fraction of the possible
peptides that can be generated from proteins of pathogenic
organisms actually generate an immune response. In order for a
peptide to stimulate a helper T lymphocyte response, it must bind
MHC II in the endocytic organelles [1].
MHC molecules are extremely polymorphic. The number of
identified human MHC (HLA) molecules has surpassed 1500 for
class I and many thousands for class II [2]. This high degree of
polymorphism constitutes a challenge for T cell epitope discovery,
since each of these molecules potentially has a unique binding
specificity, and hence a unique preference for which peptides to
present to the immune system. Even though many of the alleles
could be functionally very similar (i.e. have binding pockets that are
similar to other alleles) it is often very difficult a priori to identify
such similarities since subtle differences in binding pocket amino
acids can lead to dramatic changes in binding specificity [3].
During the last decades, prediction of T cell epitopes has
reached a level of accuracy which makes prediction algorithms a
natural and integral part of most major large scale rational epitope
discovery projects [4–6]. The single most selective event defining
T cell epitopes is the binding of peptide fragments to the MHC
complexes [7,8]. However, most efforts in developing accurate
prediction algorithms for MHC/peptide binding has focused on
MHC class I (for review see [9]). Here, large-scale epitope
discovery projects integrating high-throughput immunoassays [10]
with bioinformatics has achieved highly accurate prediction
algorithms covering large proportions of the human MHC class
I allelic polymorphism [3,11,12]. The situation for MHC class II is
quite different. Here, most prediction algorithms have been
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MHC molecules [13–24]. Very limited work has been done on
deriving HLA class II prediction algorithms with broad allelic
coverage. To our knowledge, only three such publicly available
method exists: Propred [25], ARB [17], and NetMHCII [26].
Propred is a publicly available version of the TEPITOPE method
[27], which is an experimentally derived virtual matrix-based
prediction method that covers 50 different HLA-DR alleles, and
relies on the approximation that the peptide binding specificity can
be determined solely from alignment of MHC pockets amino
acids. NetMHCII and ARB are weight matrix data-driven
methods derived from quantitative peptide/MHC binding data
and covers 14 HLA-DR alleles (as well as some mouse MHC class
II alleles). Most other HLA class II prediction methods have been
trained and evaluated on very limited data sets covering only a
single or a few different HLA class II alleles [13–23].
We have previously shown that a minimum number of 100–200
peptides with characterized binding affinity is needed to derive an
accurate description of the binding motif for MHC class II alleles
[26]. Characterizing the binding preference of each MHC molecule
would therefore be an immense and very costly undertaking. In a
recent paper, we have demonstrated that is a possible to derive
accurate predictions for any HLA class I A and B loci protein of
known sequence, by interpolating information from neighboring
HLA class I molecules which have been experimentally addressed
[3]. It would therefore seem natural to attempt as similar approach
to derive a pan-specific HLA class II prediction algorithm. For two
major reasons, however, the situation for HLA class II is very
different from HLA class I. Firstly, quantitative binding data is only
available for a few HLA class II alleles (only 14 HLA-DR alleles are
characterized by more than 100 quantitative binding data points,
the IEDB database November 2007, [28]). Secondly, the HLA class
II binding groove is open at both ends allowing binding of peptides
extended beyond the nonamer-binding core [29,30]. A prerequisite
for deriving a pan-specific binding prediction algorithm is therefore
a precise alignment of the peptide-binding core to the HLA binding
cleft. This alignment is essential since the algorithm underlying the
pan-specific binding predictions relies on the ability to capture
general features of the relationship between peptides and HLA
sequences and interpret these in terms of a binding affinity. Such
relationships can only by captured if the peptide is correctly aligned
relative to the residues in the HLA binding cleft. We have recently
published a method [26] for prediction of peptide-MHC class II
binding that covers the 14 HLA-DR alleles which are populated
with large amounts of quantitative peptide data in the IEDB
database. This method provides a predicted binding affinity value
for each peptide, together with an identification of the peptide-
binding core, and it is based upon these predictions, we have
developed this HLA-DR pan-specific method following the strategy
described in [3].
In this work, we demonstrate how a pan-specific HLA-DR
prediction method exploiting both peptide and primary HLA
sequence can be used to accurately predict quantitative binding
predictions for all HLA-DR molecules of known protein sequence.
In particular, the method is capable of predicting the specificity of
HLA-DR molecules with previously uncharacterized binding
specificities thus demonstrating the true pan-specific nature of
the method. The method and the benchmark data sets are
available at http://www.cbs.dtu.dk/services/NetMHCIIpan.
Results
We trained the pan-specific HLA-DR prediction method as
schematically illustrated in Figure 1. Both peptide sequences and
HLA primary sequence information were used as input to the
method. The peptide core and peptide flanking residues (PFR)
were identified using the stabilized matrix alignment method [26].
Multiple register peptides were presented to the method in terms
of the normalized measured binding affinity as illustrated in
Figure 1B. By including both the peptide and HLA primary
sequence, the pan-specific method is able to predict binding of
peptides to all HLA-DR molecules even in the absence of data
characterizing its binding specificity.
Leave-One-Out Validation
To validate the pan-specific method, we conducted a leave-one-
molecule out (LOO) experiment covering all 14 HLA-DR alleles
included in the IEDB data set. For each allele, an artificial neural
network (ANN) pan-specific predictor was trained as described in
Materials and Method using all peptide data from the IEDB data
set except the data for the HLA-DR molecule in question. Next,
peptide binding affinity values for the HLA-DR molecule in
question were obtained as the ANN prediction score for the
optimal nonamer peptide core. The experiment thus simulates
prediction of binding to hitherto un-characterized HLA-DR
molecules. The predictive performance for each HLA allele was
measured in terms of the AUC value [31] and Pearson’s
correlation [32]. Values for the Spearman’s rank correlation
[32] are given in Table S1. For each allele, we compared the LOO
performance to that of the TEPITOPE method [27] for the alleles
covered by this method, and a conventional single allele predictor
(SMM-align [26]) trained on data from the most closely related
HLA molecule as identified by similarity between the HLA
sequences (Neighbor).
The results shown in Table 1 clearly demonstrate the predictive
power of the pan-specific LOO method. The LOO approach
achieves the highest predictive performance for all 11 alleles
covered by TEPITOPE, and only for two alleles (DRB1*1302,
and DRB4*0101) is the performance of the single allele neighbor
method (SMM-align) better than that of the pan-specific LOO
method. These differences are statistically significant (p,0.001 and
p=0.001, respectively, Binomial test).
Author Summary
CD4 positive T helper cells provide essential help for
stimulation of both cellular and humoral immune reac-
tions. T helper cells recognize peptides presented by
molecules of the major histocompatibility complex (MHC)
class II system. HLA-DR is a prominent example of a human
MHC class II locus. The HLA molecules are extremely
polymorphic, and more than 500 different HLA-DR protein
sequences are known today. Each HLA-DR molecule
potentially binds a unique set of antigenic peptides, and
experimental characterization of the binding specificity for
each molecule would be an immense and highly costly
task. Only a very limited set of MHC molecules has been
characterized experimentally. We have demonstrated
earlier that it is possible to derive accurate predictions
for MHC class I proteins by interpolating information from
neighboring molecules. It is not straightforward to take a
similar approach to derive pan-specific HLA-DR class II
predictions because the HLA class II molecules can bind
peptides of very different lengths. Here, we nonetheless
show that this is indeed possible. We develop an HLA-DR
pan-specific method that allows for prediction of binding
to any HLA-DR molecule of known sequence—even in the
absence of specific data for the particular molecule in
question.
Pan-Specific HLA-DR Binding Predictions
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the ability to interpolate information from ‘‘neighboring’’ alleles in
HLA specificity space and interpret this information in terms of
binding affinities. It is thus expected that the pan-specific method
should perform best in cases where closely related HLA molecules
are included in the training of the method. The data in Table 1
Figure 1. Schematic Illustration of the NetMHCIIpan Method. (A) The HLA-DR pseudo sequence is constructed from polymorphic HLA-DR
residues in potential contact with a bound peptide. (B) Position specific scoring matrix (PSSM) and peptide core alignment (shown in red) is made for
each allele using the SMM-align method [26]. N and C terminal peptide flanking regions, PFR, are identified as the up to three amino acids flanking
the peptide-binding core. (C) Suboptimal peptides are presented to the NetMHCpan method with binding values normalized to the optimal peptide
score (for the peptide shown in red) as described in Materials and Methods. (D) The NetMHCIIpan method is trained integrating data from all alleles.
Input to the artificial neural network training includes the peptide core, composition and length of the N and C terminal PFR, length of the source
peptide as well as the normalized binding affinity value (for details see Materials and Methods).
doi:10.1371/journal.pcbi.1000107.g001
Table 1. Leave-One-Molecule-Out Benchmark Results in Terms of the AUC and Pearson’s Correlation Values.
AUC Pearson Neighbor
Allele N LOO Neighbor TEPITOPE LOO Neighbor Dist Allele
DRB1*0101 5166 0.778 0.736 0.720 0.570 0.489 0.352 DRB1*0401
DRB1*0301 1020 0.746 0.679 0.664 0.449 0.337 0.277 DRB3*0101
DRB1*0401 1024 0.775 0.726 0.716 0.598 0.503 0.066 DRB1*0405
DRB1*0404 663 0.852 0.808 0.770 0.684 0.596 0.091 DRB1*0401
DRB1*0405 630 0.808 0.793 0.759 0.597 0.557 0.066 DRB1*0401
DRB1*0701 853 0.825 0.760 0.761 0.655 0.544 0.504 DRB1*0901
DRB1*0802 420 0.841 0.827 0.766 0.631 0.575 0.111 DRB1*1101
DRB1*0901 530 0.653 0.639 0.388 0.369 0.431 DRB5*0101
DRB1*1101 950 0.799 0.696 0.721 0.588 0.401 0.084 DRB1*1302
DRB1*1302 498 0.658 0.675 0.652 0.351 0.343 0.084 DRB1*1101
DRB1*1501 934 0.738 0.705 0.686 0.535 0.489 0.295 DRB1*0404
DRB3*0101 549 0.716 0.686 0.444 0.368 0.277 DRB1*0301
DRB4*0101 446 0.724 0.726 0.469 0.422 0.397 DRB1*0404
DRB5*0101 924 0.831 0.810 0.680 0.633 0.592 0.295 DRB1*1101
Ave* 14607 0.768 0.733 0.541 0.470
Ave** 0.787 0.747 0.718
The table gives the allele name, the number of peptides included in the IEDB data for each allele, the LOO, the nearest neighbor SMM-align [26] and TEPITOPE [27]
performances, the later only for subset of alleles covered by that method. In bold is highlighted the highest performance for each allele. The Ave* and Ave** rows give
the average performance over all 14 alleles, and over the 11 alleles covered by the TEPITOPE method, respectively.
doi:10.1371/journal.pcbi.1000107.t001
Pan-Specific HLA-DR Binding Predictions
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two outliers DRB1*1302, and DRB1*0701 the plot shows the
clear relation that alleles with close nearest neighbors tend to be
predicted with a higher accuracy compared to alleles with large
distances to their nearest neighbor.
Cross-Validation
Next, the final NetMHCIIpan method was trained on the
complete datasets in a fivefold cross-validated manner abandoning
the leave-one-out approach (see Materials and Methods). We
compare the performance of the NetMHCIIpan method to that of a
conventional single allele prediction method (SMM-align) and the
TEPITOPE method in terms of both the AUC values and the
Pearson’s correlation coefficient (the latter is only included for the
NetMHCIIpan and SMM-align methods, since the TEPITOPE
method does not provide output values that are linearly related to
the peptide binding affinity). The summary of this benchmark
calculation is shown in Figure 3 (for details see Table S2).
The results show how the pan-specific method is capable of
integrating information from neighboring HLA-DR molecules,
and thus boosting the predictive performance beyond that of the
conventional single allele methods like SMM-align and TEPI-
TOPE. For all 14 alleles included in the benchmark, the pan-
specific method outperforms the two other methods (p,0.001,
Binominal test).
Validation Using a Hitherto Uncharacterized HLA-DR
Molecule
The ultimate validation of a pan-specific method for HLA-DR
peptide binding predictions would be to identify which peptides
Figure 2. Predictive Performance in Terms of the Pearson’s Correlation of the LOO Pan-Specific Method as a Function of the
Distance to Its Nearest Neighbor HLA-DR Allele. The nearest neighbor distance is estimated as described in Materials and Methods.
doi:10.1371/journal.pcbi.1000107.g002
Figure 3. Cross-Validation Benchmark Evaluation. The predictive performance of the pan-specific, SMM-align, and TEPITOPE methods
compared in terms of the Pearson’s correlation and AUC values averaged over the 11 alleles covered by the TEPITOPE method, respectively (data for
the individual alleles is given in Table S2).
doi:10.1371/journal.pcbi.1000107.g003
Pan-Specific HLA-DR Binding Predictions
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We therefore conducted such an experiment where a set of 256
15mer peptides were tested in an in vitro binding assay for binding
to the HLA-DRB1*0813 molecule (described in materials and
methods). Of the 20 top scoring peptides, 75% were shown to bind
with a KD values below 1000 nM, and 50% were shown to bind
stronger than 50 nM. A performance summary of this experiment
is shown in Table 2. This experiment demonstrates how the pan-
specific prediction approach can identify peptide-binding motifs
even in the absence of any data for the specific query HLA-DR
molecule.
Identifying Endogenously Presented Peptides
The NetMHCIIpan method was further validated using a large
set of data from the SYFPEITHI database [29], which were not
included in the training data of the NetMHCIIpan method. This set
consists of 584 HLA ligands restricted to 28 different HLA-DR
alleles. For every peptide, the source protein was found in the
SwissProt database [33]. If more than one source protein was
possible, the longest protein was chosen. The source protein was
split into overlapping peptide sequences of the length of the HLA
ligand. All peptides except the annotated HLA ligand were taken
as negative peptides. We are aware that this is a strong
assumption, since suboptimal peptides that could be presented
on the HLA molecule are counted as negatives. For each protein-
HLA ligand pair the predictive performance was estimated as the
AUC value. The summary of this benchmark calculation is shown
in Figure 4 (for details see Table S3).
The NetMHCIIpan and TEPITOPE methods have similar
predictive performance on the subset of 17 alleles covered by
both methods. The TEPITOPE method has the highest
performance for 10 alleles and the NetMHCIIpan the highest
performance for 7 alleles (this difference is not significant p.0.3,
Binomial test). For the 11 alleles not covered by the TEPITOPE
method, NetMHCIIpan achieves the highest performance for 9
alleles, and the TEPITOPE method the highest performance for 2
alleles. For these alleles, NetMHCIIpan thus performs significantly
better than the TEPITOPE method (p,0.01, Binominal test).
Finally, for the 14 alleles not covered by the SMM-align method,
and thus not included in the training of the pan-specific method,
NetMHCIIpan achieves a higher performance than the TEPITOPE
method. However, this difference is not significant. Also, in this
experiment the NetMHCIIpan method performs particularly poorly
compared to the TEPITOPE method on the DRB1*13 alleles.
Using a network ensemble trained by leaving out the binding data
for the DRB1*1302 allele, the average predictive performance for
the DRB1*1302 allele is improved from 0.567 to 0.747 (data not
shown). This result confirms our earlier observation that the
DRB1*1302 allelic data included in the training of the
NetMHCIIpan method forms an outlier group with unusual binding
specificity characteristics.
Identification of Peptide Binding Core
To validate the ability of the NetMHCIIpan method to correctly
identify the binding core of peptides bound to MHC class II
molecules, we compiled from the PDB database [34] a set of 15
peptides which have been crystallized in complex with an HLA-
DR allele. For these peptides, we can identify the exact peptide
binding by manual extracting which peptide residue is bound in
the P1 pocket and subsequently test if this core can be identify by
Table 2. Prospective Validation Using an Hitherto
Uncharacterized HLA Molecule.
AUC
Spearman’s rank
correlation
Pearson’s
correlation
Pan-specific 0.783 0.582 0.567
TEPITOPE 0.769 0.547
Predictive performance values for the Pan-specific and TEPITOPE [27] methods,
respectively, on a set of 256 15mer peptides. The AUC value (area under the
operator receiver curve) was calculated using an IC50 binding threshold value
of 500 nM. Note, that the Pearson’s correlation is not informative for the
TEPITOPE method since this method gives large negative (2999) scores to
disfavored amino acids on certain positions.
doi:10.1371/journal.pcbi.1000107.t002
Figure 4. Prediction of Endogenously Presented Peptides. The benchmark data set consists of 584 HLA-DR restricted ligands covering 28
HLA-DR alleles downloaded from the SYFPEITHI database as described in the text. For alleles not covered by the TEPITOPE method, the closest allele
covered by the TEPITOPE method as identified by sequence similarity between the HLA pseudo-sequences is used. TEPITOPE Alleles give the average
AUC performance over the 17 alleles covered by the TEPITOPE method, and non-TEPITOPE Alleles give the average AUC performance over the 11
alleles not covered by the TEPITOPE method (data for the individual alleles is given in Table S3).
doi:10.1371/journal.pcbi.1000107.g004
Pan-Specific HLA-DR Binding Predictions
PLoS Computational Biology | www.ploscompbiol.org 5 July 2008 | Volume 4 | Issue 7 | e1000107the prediction method. As demonstrated in Table 3, both the
TEPITOPE and NetMHCIIpan methods are capable of identifying
the binding core of the 15 peptides. TEPITOPE correctly
identifies all 15 binding cores, whereas the NetMHCIIpan misaligns
one peptide by a single amino acid residue.
HLA-DR Allelic Specificity Clustering
It has previously been shown that HLA-A and HLA-B class I
molecules can be clustered into a limited number of groups also
known as supertypes sharing common binding specificity charac-
teristics. A similar clustering of HLA-DR alleles has also been
proposed [35]. In order to validate and extend this clustering, the
NetMHCIIpan method was used to cluster HLA-DR molecules
according to predicted peptide binding specificity. Pruned HLA
distance trees were calculated as described in Materials and
Methods. Figure 5 depicts a tree including 76 representatives of
the currently known HLA-DR molecules.
The overall structure of the HLA-DR specificity tree is in
accordance with the previously proposed clustering [35] contain-
ing 12 main supertypes. It is, however, striking to observe the high
degree of serotype mixing between the different supertype clusters.
Almost all of the proposed supertypes contain HLA-DR molecules
from more than one serotype. This has earlier been observed when
defining HLA-DR specific clusters based on the TEPITOPE
binding matrices [35], but not to the degree suggested by the
analysis presented here.
Discussion
The MHC molecules are extremely polymorphic giving rise to
many different peptide-binding specificities being expressed in the
human population. More than 500 different HLA-DR molecules
and more than 2000 different HLA-DQ and HLA-DP molecules
have been described [2]. The only partially pan-specific HLA-DR
prediction algorithm publicly available is the TEPITOPE method
[27]. This method describes binding of peptides to 50 HLA-DR
molecules. However, as shown in this work, the TEPITOPE
method leaves large portions of the HLA-DR allelic polymorphism
undescribed.
In the present work, we develop a HLA-DR pan-specific method,
NetMHCIIpan, capable of providing quantitative predictions of
peptide binding to all HLA-DR molecules with known protein
sequence. The method is based on artificial neural networks and is
trained on quantitative peptide HLA-DR binding data including
the peptide-binding core, peptide flanking residues, and the HLA-
DR residues estimated to be within interaction distance of the
bound peptide. The natural strength of the method is the ability to
predict binding of peptides to any HLA-DR molecule, thus being
truly HLA-DR pan-specific. Further, since the method is artificial
neural network based, it can capture non-linear relationships
defining the binding specificity both within the peptide and between
the peptide and the HLA molecule. This is fundamentally different
from the methodology underlying the TEPITOPE method, that
relies on the approximation that peptide binding specificities can be
determined as a summation over independent HLA pockets
preferences. The method is validated in terms of prediction of
peptide binding to hitherto un-characterized HLA-DR molecules,
large-scale leave-one-out experiments, cross-validation and identi-
fication of endogenously presented peptides and experimentally
validated binding cores. In all validation experiments, the
NetMHCIIpan method was shown to perform better than or
comparable to TEPITOPE, the only other partially HLA-DR
pan-specific binding prediction method publicly available.
A powerful application of the HLA-DR pan-specific prediction
algorithm would be to search for highly promiscuous peptide
sequences that will bind to most HLA-DR alleles. Such peptides
could be of high value in the development of synthetic and
recombinant vaccines, since they would bind universally in most
humans independently of MHC class II genetic background and
thus potentially provide universal helper T cell activation. By way
of example, we applied the pan-specific method to identify
peptides, predicted to bind a set of prevalent HLA-DR alleles.
Prevalent alleles were selected as HLA-DR alleles with a maximal
Table 3. Identification of Peptide Binding Cores.
HLA-DRB PDB ID Length Peptide sequence Core TEPITOPE NetMHCIIpan
DRB1*0101 2FSE 14 AGFKGEQGPKGEPG FKGEQGPKG FKGEQGPKG FKGEQGPKG
DRB1*0101 1KLG 15 GELIGILNAAKVPAD IGILNAAKV IGILNAAKV IGILNAAKV
DRB1*0101 1SJE 16 PEVIPMFSALSEGATP VIPMFSALS VIPMFSALS VIPMFSALS
DRB1*0101 1FYT 13 PKYVKQNTLKLAT YVKQNTLKL YVKQNTLKL YVKQNTLKL
DRB1*0101 1AQD 15 VGSDWRFLRGYHQYA WRFLRGYHQ WRFLRGYHQ WRFLRGYHQ
DRB1*0101 1PYW 11 XFVKQNAAALX FVKQNAAAL FVKQNAAAL FVKQNAAAL
DRB1*0101 1T5X 15 AAYSDQATPLLLSPR YSDQATPLL YSDQATPLL YSDQATPLL
DRB1*0301 1A6A 15 PVSKMRMATPLLMQA MRMATPLLM MRMATPLLM MRMATPLLM
DRB1*0401 2SEB 12 AYMRADAAAGGA MRADAAAGG MRADAAAGG YMRADAAAG
DRB1*0401 1J8H 13 PKYVKQNTLKLAT YVKQNTLKL YVKQNTLKL YVKQNTLKL
DRB1*1501 1BX2 15 ENPVVHFFKNIVTPR VHFFKNIVT VHFFKNIVT VHFFKNIVT
DRB1*1501 1YMM 23 ENPVVHFFKNIVTPRGGSGGGGG VHFFKNIVT VHFFKNIVT VHFFKNIVT
DRB5*0101 1H15 14 GGVYHFVKKHVHES YHFVKKHVH YHFVKKHVH YHFVKKHVH
DRB5*0101 1FV1 20 NPVVHFFKNIVTPRTPPPSQ FKNIVTPRT FKNIVTPRT FKNIVTPRT
DRB5*0101 1ZGL 15 VHFFKNIVTPRTPGG FKNIVTPRT FKNIVTPRT FKNIVTPRT
The table shows HLA-DR restricted peptides compiled from the PDB database [34]. The columns in the table give the HLA-DR restriction, the PDB identifier, and peptide
length and peptide amino acid sequences, respectively. The last columns give the binding core as extracted from the protein complex crystal structure, and the core as
predicted by the TEPITOPE and NetMHCIIpan methods, respectively.
doi:10.1371/journal.pcbi.1000107.t003
Pan-Specific HLA-DR Binding Predictions
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Middleton et al. [36]. In doing so, we could identify peptides
predicted to bind promiscuously to all prevalent HLA-DR
molecules. Earlier efforts have been made to identify such highly
promiscuous peptides. The PADRE sequence [37] is one of the
most prominent examples of such peptides. Using the pan-specific
method, the PADRE sequence is predicted to bind to less than
40% of the prevalent HLA-DR molecules. The analysis shown
here demonstrates that exhaustive searches for truly pan-
promiscuous HLA-DR are indeed feasible using the proposed
pan-specific method.
The pan-specific approach relies on the ability of the neural
networks to capture general features of the relationship between
peptides and HLA sequences and interpret these in terms of a
binding affinity. For this approach to provide reliable predictions,
it is essential that polymorphism of the HLA molecules described
by the pan-specific method is to some degree covered by the data
included in the training of the method. For the NetMHCIIpan
prediction method, we have included binding data covering only
14 of the more than 500 known HLA-DR molecules [2], thus very
likely leaving large regions of the HLA specificity space uncovered.
On the basis of the specificity clustering shown in Figure 5, we can
identify HLA-DR alleles with un-characterized binding specific-
ities as these alleles are found far from the alleles included in the
training of the pan-specific method. Such novel HLA-DR
molecules include the DRB1*14 molecules, i.e., DRB1*1407
(12.5%) and some of the DRB1*11, like DRB1*1103 (5%), as well
as DRB1*12 alleles like DRB1*1202 (35%) placed close to center
of the tree. The number in parenthesis after each allele is the
maximal allelic frequency in an ethnic population as reported by
Middleton et al. 2003 [36].
We have previously shown how integrative approaches
combining bioinformatics and immunoassays to identify and
experimental assay peptide with uncharacterized binding affinity
can improve the prediction accuracy of peptide/MHC class I
prediction algorithms [38]. Using the pan-specific approach to
identify HLA class II molecules with uncharacterized binding
specificities, we suggest extending this search strategy into the
dimension of MHC polymorphism. A schematic illustration of this
search strategy integrating bioinformatics and high throughput
immunoassays is shown in Figure 6.
Here, we illustrate an iterative cycle that identifies novel MHC
molecules with predicted binding specificities that are dissimilar to
the specificities included in the training of the pan-specific method.
Next, immunoassays should be developed describing the binding
specificity of these molecules by identifying peptides with un-
characterized binding affinity, and experimentally assay these
peptides. Such an approach should allow for rapid and efficient
sampling of both the MHC polymorphism and the diversity of
peptide binding.
The current version of NetMHCIIpan and the benchmark data
used in this work is available at http://www.cbs.dtu.dk/services/
Figure 5. HLA-DR Clustering from NetMHCIIpan Predictions. The figure shows the clustering for 76 representative HLA-DR alleles. The tree was
generated using the neighbor-joining algorithm from HLA distance matrices as described in the text. The circles are guides to the eye highlighting
the suggested 12 HLA-DR supertypes.
doi:10.1371/journal.pcbi.1000107.g005
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known protein sequence. The method will be updated as more
data becomes available. In the future, it is our hope to extend the
method to also cover HLA-DQ and HLA-DP molecules.
Materials and Methods
Data
Quantitative HLA-DR restricted peptide-binding data was
obtained from the IEDB database [28] and from an in-house
collection of unpublished data [Bjorn Peters, private communica-
tion]. For external evaluation of the pan-specific method, we
included a set of HLA-DR class II ligands from the SYFPEITHI
database [29]. Only ligands not included in the quantitative HLA-
DR restricted peptide binding data set were used. The
SYFPEITHI data set consists of 584 MHC ligands restricted to
28 HLA-DR alleles. The details on the data set is given is Tables
S4 and S5 (the complete data sets are available at http://www.cbs.
dtu.dk/suppl/immunology/NetMHCIIpan.php).
Method
The pan-specific HLA-DR method was constructed as de-
scribed in Figure 1. The peptide nonamer core and peptide-
flanking residues (PFR) were identified for each of the peptides in
the IEDB dataset using the SMM-align method [26]. The SMM-
align method identifies of the maximal scoring nonamer peptide
core for each peptide sequence. This approach will thus leave out
information on the suboptimal nonamer sequences that are
predicted not to bind or to bind with a weaker affinity. To
include information on the binding affinity for these suboptimal
nonamer peptides, we assign a normalized binding score, Snorm,t o
suboptimal nonamer peptides given as the ratio of the SMM-align
score for the peptide to the SMM-align score of the optimal
peptide multiplied with the log-transformed experimental IC50
binding value of the peptide. That is Snorm=(S/SM)M, where S is
the SMM-align score for the (suboptimal) peptide, SM is the SMM-
align score of the optimal peptide, and M is the binding value log-
transformed as 12log50k(aff), where aff is the experimental IC50
binding value of the full-length peptide, and log50k is the logarithm
with base 50.000. In case the SMM-align method assigns the
maximal scoring nonamer peptide a log-transform binding value
of 0, the log-transformed experimental IC50 binding value is
assigned randomly to one of the suboptimal peptides and all other
nonamer peptides are given a binding value of 0. In doing this
expansion using sub-optimal nonamer peptides, the size of the
IEDB dataset was enlarged from 14,607 to more than 100,000
data points. This more than 5 fold increase of the data gave
consistent improvements to the accuracy of the prediction method
in all benchmark calculations (data not shown).
For each peptide core, the PFRs were identified as the amino
acids flanking the peptide core up to a maximum of three at either
end.
HLA Pseudo-Sequence
The HLA sequence was encoded in terms of a pseudo-sequence
consisting of amino acid residues in contact with the peptide. The
contact residues are defined as being within 4.0 A ˚ of the peptide in
any of a representative set of HLA class II structures. Only
residues polymorphic in any known HLA-DR, DQ and DP
protein sequence were included giving rise to a pseudo-sequence
consisting of 21 amino acid residues. The HLA class II pseudo-
sequence is described in detail in Table S6.
Neural Network Training
Artificial neural networks (ANN) were trained to quantitatively
predict peptide-HLA binding as described in Nielsen et al. [3].
The input sequences were presented to the neural network in three
distinct manners: (a) conventional sparse encoding (i.e., encoded
by 19 zeros and a one), (b) Blosum encoding, where each amino
acid was encoded by the BLOSUM50 matrix score vector [39],
and (c) a mixture of the two, where the peptide was sparse encoded
and the HLA pseudo sequence was Blosum encoded. PFRs were
calculated as the average BLOSUM62 score over a maximum
length of three amino acids [26]. The PFR length was encoded as
LPFR/3, 12LPFR/3, where LPFR is the length of the PFR (between
0 and 3), and the peptide length was encode as LPEP,1 2LPEP,
where LPEP=1/(1+exp((L215)/2)) and L is the peptide length. For
each data point, the input to the neural network thus consists of
the peptide sequence (9620=180 inputs), the PFRs (2620=40
inputs), the HLA pseudo sequence (21620=420 inputs), the
peptide length (2 inputs), and the length of the C and N terminal
PFR’s (262=4 inputs) resulting in a total of 646 input values.
To estimate the predictive performance of the method, the
leave-one-out (LOO) experiment was conducted as described by
Nielsen et al. [3]. For each HLA-DR molecule, a neural network
ensemble was trained using all available data, excluding all data
specific for the HLA-DR allele in question. Network architectures
with hidden neurons of 22, 44, 56, and 66 were used. The network
training was performed in a fivefold cross-validated manner using
the three encoding schemes described above resulting in an
ensemble of 60 neural networks (3 encoding schemes, 4
architectures, and 5 folds). The predicted affinity for a peptide
was then determined as prediction value for the maximal scoring
nonamer peptide core (including PFRs), where each nonamer
peptide core is scored as the average of the 60 predictions in the
neural network ensemble.
For the final NetMHCIIpan method, a conventional five-fold
cross-validated training was performed. The pool of unique
peptides was randomly split into five groups with all HLA binding
data for a given peptide placed in the same group (in this way, no
peptide can belong to more than one group).
Nearest Neighbor Distance
The nearest neighbor distance between two HLA alleles is
estimated from the alignment score of the HLA pseudo sequences
Figure 6. Strategy for Effective and Rational Coverage of the
MHC Polymorphism and Specificity. (A) The pan-specific MHC class
II prediction method is used to identify MHC alleles with novel binding
specificities. These alleles have a predicted binding motif that is distant
to all MHC class II molecules previously described. Subsequently,
immunoassays are developed describing their binding specificity and
data is fed back into a retraining of the pan-specific method. (B) Next,
peptides with un-characterized binding affinity (high information
peptides) are identifies, experimentally assayed and fed back into the
retraining.
doi:10.1371/journal.pcbi.1000107.g006
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1/2, where s(A,B) is the
BLOSUM50 alignment score [39] between the pseudo sequences
A and B, respectively.
HLA Distance Trees
HLA distance trees were derived from correlations between
predicted binding affinities as described by Nielsen et al. [3]. In
order to visualize the HLA distance tree, only a subset of the leaves
in the tree was displayed. The subset was selected in a Hobohm 1-
like manner, where the alleles were clustered at a 0.95 distance
level and only a single allele from each cluster selected for display
[40].
In Vitro Binding Assay
The extracellular parts of HLA DRA1*0101 and HLA
DRB1*0813 were fused to the Fos Jun leucine zipper dimerization
motifs as previously described [41]. Both chains were separately
expressed as inclusion bodies in E. coli (BL21) using standard IPTG
induction. The two chains were extracted from inclusion bodies
and purified by anion exchange and gel filtration chromatography
under denaturing conditions. Equimolar concentrations of alpha
and beta chain were diluted into a refolding buffer containing a
titration of peptide (0–15 mM). After 48 h of incubation at 18uC
the concentration of formed complex was determined by a
quantitative ELISA using the HLA-DR specific monoclonal
antibody L243. The data was fitted to a saturation curve using
non-linear regression and the Kd value determined.
Supporting Information
Table S1. Leave-One-Molecule Out (LOO) Benchmark Results
in Terms of the Spearman’s Rank Correlation. The table gives the
allele name, the number of peptide included in the IEDB data for
each allele, the LOO performance, the nearest neighbor SMM-
align [26] performance together with the distance to that neighbor
and the neighbor allele name and the performance of the
TEPITOPE method [25,27] for the subset of alleles covered by
that method. The Ave* row give the average performance over all
14 alleles, and the Ave** row gives the average performance over
the 11 alleles covered by the TEPITOPE method.
Found at: doi:10.1371/journal.pcbi.1000107.s001 (0.08 MB
DOC)
Table S2. Cross-Validated Benchmark Calculation. The pre-
dictive performance between the pan-specific, SMM-align, and
TEPITOPE methods compared in terms of the AUC value and
Pearson’s correlation. The first column gives the allele name, the
second column gives the number of data included for each allele,
the third and fourth columns give the predictive performance for
the pan-specific method, the sixth and seventh columns the
predictive performance for the SMM-align method, and the last
column the predictive performance for the TEPITOPE method.
The Ave* row give the average performance over all 14 alleles,
and the Ave** row gives the average performance over the 11
alleles covered by the TEPITOPE method.
Found at: doi:10.1371/journal.pcbi.1000107.s002 (0.08 MB
DOC)
Table S3. Prediction of Endogenously Presented Peptides. The
benchmark data set consists of 584 HLA-DR restricted ligands
covering 28 HLA-DR alleles downloaded from the SYFPEITHI
database as described in the text. The table gives the allele name,
the number of HLA ligands restricted to each allele, and the
average AUC values for the ligands restricted to each allele for the
NetMHCIIpan (PAN), and TEPITOPE methods, respectively.
The last two columns indicate if the allele is covered (v) by the
SMM-align (in PAN) and TEPITOPE (in TEPITOPE) methods,
respectively, or not. If the allele is not covered by the TEPITOPE
method, the closest allele covered by the TEPITOPE method as
identified by sequence similarity between the HLA pseudo-
sequences is used. Ave* and Ave** give the average performance
over all 28 alleles and the 17 alleles covered by the TEPITOPE
method, respectively. Ave*** gives the average performance over
the 11 alleles not covered by the TEPITOPE method, and
Ave**** gives the average performance for the 14 alleles not
covered by the SMM-align method.
Found at: doi:10.1371/journal.pcbi.1000107.s003 (0.08 MB
DOC)
Table S4. IEDB Quantitative HLA-DR Restricted Peptide
Binding Data. 14 HLA-DR alleles are covered by the data set.
The first column gives the HLA-DR allele, the second column the
number of peptide data for each allele, and the third and fourth
columns give the number of peptide binders/non-binders,
respectively. Peptide binders are classified using an IC50 threshold
value of 500 nM.
Found at: doi:10.1371/journal.pcbi.1000107.s004 (0.05 MB
DOC)
Table S5. The SYFPEITHI Data Set. HLA-DR ligands
downloaded from the SYFPEITHI database [29]. The first and
third columns give the allele names, and the second and fourth
column give the number of HLA-DR ligands for each allele.
Found at: doi:10.1371/journal.pcbi.1000107.s005 (0.05 MB
DOC)
Table S6. The HLA Class II Pseudo-Sequence. The table shows
the HLA class II pseudo-sequence. The columns gives the pseudo
sequence position, the HLA residue numbering according to the
IMGT nomenclature [2], and the amino acid polymorphism at
each position in the pseudo sequence for known HLA-DR, DP
and DQ loci protein sequences (as of November 2007). Note, that
the DPB protein sequence has a deletion of two amino acids at
position 24–25 compared to DRB. The DQB sequence numbering
for DPB after position 25 is off by two. For DPB position 26 thus
corresponds to position 24 in the DPB protein sequence.
Found at: doi:10.1371/journal.pcbi.1000107.s006 (0.09 MB
DOC)
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